3:21 PM · 28 September 2020

Inovio’s stock plunged as COVID vaccine trial is put on hold

Inovio Pharmaceuticals (INO.US) stock tumbled 32% after the company announced that the Phase 2/3 clinical trial for its coronavirus vaccine candidate had been halted while it answered additional questions from the Food and Drug Administration. Company is planning to respond to the FDA in October, and then the agency has 30 days to issue its decision about whether the trial can move forward.

Inovio Pharmaceuticals (INO.US) stock launched today’s session with a bearish price gap and is currently testing major resistance at $11.00 per share which is additionally strengthened by 200 MA (red line). If sellers manage to break below it, a downward impulse towards $6.03 per could be launched. On the other hand, once buyers regain control, the resistance at $16.53 per share may be at risk. Source: xStation5

30 July 2026, 6:38 AM

Morning Wrap: Markets Are Trying to Rebound Following Big Tech Earnings and the Fed's Decision

29 July 2026, 9:56 PM

Meta shows how to lose almost 10% despite record sales due to AI development

29 July 2026, 9:54 PM

Microsoft shows how to make money on data centers. AI investments are starting to pay off

29 July 2026, 3:57 PM

Meta Preview: Will Advertising Fund Its AI Ambitions?

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits